Apellis Pharmaceuticals (APLS) grants 36,606 RSUs to top officer

Rhea-AI Filing Summary

Apellis Pharmaceuticals’ Chief Business & Strat Officer Mark DeLong received an award of 36,606 shares of common stock on January 28, 2026 as a restricted stock unit grant. These RSUs vest 25% each year over four years, contingent on continued service. Following this grant, DeLong directly beneficially owns 114,959 shares of Apellis common stock.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider DeLong Mark Jeffrey

Role Chief Business & Strat Officer

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	36,606	$0.00	--

Holdings After Transaction: Common Stock — 114,959 shares (Direct)

Footnotes (1)

1. [object Object]

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

DeLong Mark Jeffrey

(Last) (First) (Middle)

C/O APELLIS PHARMACEUTICALS, INC.

100 FIFTH AVENUE, 3RD FLOOR

(Street)

WALTHAM MA 02451

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Apellis Pharmaceuticals, Inc. [ APLS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Business & Strat Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/28/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/28/2026		A		36,606(1)	A	$0	114,959	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This represents a Restricted Stock Unit award granted on January 28, 2026 that vest 25% annually over four years from grant date subject to continued service.

	/s/ David Watson, attorney-in-fact for Mark DeLong	01/30/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Apellis Pharmaceuticals (APLS) disclose about Mark DeLong’s new equity grant?

Apellis Pharmaceuticals disclosed that Chief Business & Strat Officer Mark DeLong received 36,606 shares of common stock through a restricted stock unit award granted on January 28, 2026. The award increases his directly held beneficial ownership to 114,959 common shares.

How many Apellis shares did Mark DeLong receive in the January 28, 2026 grant?

Mark DeLong received 36,606 shares of Apellis common stock via a restricted stock unit award granted on January 28, 2026. The units were granted at a price of $0 per share, reflecting a compensatory, not open-market, transaction.

What is the vesting schedule for Mark DeLong’s 36,606 Apellis RSUs?

The 36,606 restricted stock units granted to Mark DeLong vest 25% annually over four years from the January 28, 2026 grant date. Vesting is subject to his continued service, meaning portions become earned each year he remains with the company.

How many Apellis common shares does Mark DeLong own after this Form 4 transaction?

After the reported restricted stock unit grant, Mark DeLong beneficially owns 114,959 shares of Apellis common stock. This figure reflects his directly held ownership following the January 28, 2026 equity award reported in the transaction table.

Was Mark DeLong’s Apellis stock award an open-market purchase or compensation grant?

The transaction was a compensation grant, not an open-market purchase. It is reported with transaction code “A” at a price of $0 per share and described as a restricted stock unit award subject to vesting over four years with continued service.

What role does Mark DeLong hold at Apellis Pharmaceuticals (APLS)?

Mark DeLong serves as Chief Business & Strat Officer at Apellis Pharmaceuticals. The Form 4 indicates he is an officer of the company, and the reported 36,606-share restricted stock unit award is part of his equity-based compensation in that role.